A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease

NCT ID: NCT06221254

Last Updated: 2024-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2026-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psychological intervention by COBMINDEX application to reduce psychological stress among CD patients, fatigue and pain and improve the patients' well being, quality-of-life and disease-coping skills, as well as improvement of the patients' immunological profile and intestinal microbiome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

200 patients will be randomly divided into two groups - 100 patients will learn and practice COBMINDEX by a human therapist-social worker and 100 patients will learn and practice COBMINDEX by a digital therapist using the COBMINDEX application.

In the first 3-months there will be an assessment of patient progress following randomization to human therapist or digital therapist using the application for learning and practicing. During this period, the group of the human social-worker will have a limited access to the application dedicated for daily exercises and assessment.

In the following 9-month period, all patients will practice using the application, each group by it's permissions.

There will be daily assessment of stress, pain, fatigue, well-being and frequent assessments of patients' medical, psychological, and immunological status.

Throughout the trial, adverse events and concomitant medications will be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

200 CD patients divided into two equal groups: Intervention and control.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention- COBMINDEX application

The intervention in this arm is to learn during the first 3 months, cognitive, behavioral and mindfulness based stress reduction with daily exercise using a research dedicated application. Than, additional 9 months of practicing daily only with the application.

Group Type EXPERIMENTAL

COBMINDEX digital application

Intervention Type BEHAVIORAL

COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques and practices using digital application.

Control- COBMINDEX with Human therapist

The intervention in this arm is to learn during the first 3 months, cognitive, behavioral and mindfulness based stress reduction with daily exercise with human therapist, and than practicing daily only with the application.

Group Type ACTIVE_COMPARATOR

Human therapist (Control)

Intervention Type BEHAVIORAL

COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques from a human therapist (the comperator for learning from the application) and practices using digital application.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COBMINDEX digital application

COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques and practices using digital application.

Intervention Type BEHAVIORAL

Human therapist (Control)

COBMINDEX is a Cognitive, behavioral and mindfulness-based stress reduction with daily self-exercise. The intervention comprises of 7 sessions in which stress reduction techniques are learned. In this arm the Patient learns techniques from a human therapist (the comperator for learning from the application) and practices using digital application.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willingness to participate and signed informed consent
* Hebrew-speaking
* Age 18-75
* Proven diagnosis of Crohn's disease, at least 3 months post-diagnosis
* Stable medical treatment for the last 3 months
* Any Harvey Bradshaw Index score
* Ability to operate a smartphone and cellular application

Exclusion Criteria

* Diagnosis of ulcerative colitis or unclassified inflammatory bowel disease
* Planned surgery for Crohn's disease
* Surgery for Crohn's disease (excluding drainage of perianal abscess) in the last 3 months
* Psychiatric disease (schizophrenia, major depression or bipolar disorder)
* Alcohol or drug dependency (stable medical use of cannabinoids will be allowed)
* Pregnancy or planned pregnancy during study period
* Clinically significant comorbidity
* Former participation in COBMINDEX trials
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Leona M. and Harry B. Helmsley Charitable Trust

OTHER

Sponsor Role collaborator

Ben-Gurion University of the Negev

OTHER

Sponsor Role collaborator

Soroka University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Doron Schwartz

Senior Physician, Department of Gastroenterology and Hepatology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ruthie Bekore, MPH

Role: STUDY_DIRECTOR

Soroka University Medical Center

Ganit Goren, PhD

Role: STUDY_DIRECTOR

Ben-Gurion University of the Negev

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Soroka University Medical Center

Beersheba, , Israel

Site Status RECRUITING

Rambam Health Care Campus i

Haifa, , Israel

Site Status NOT_YET_RECRUITING

Belinson Medical Center

Petah Tikva, , Israel

Site Status NOT_YET_RECRUITING

Sheba Medical Center

Ramat Gan, , Israel

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Doron Schwartz, MD

Role: CONTACT

+972-52-3919044

Shmuel Odes, MD

Role: CONTACT

+972-52-2700752

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Doron Schwartz, MD

Role: primary

+972523919044

Shmuel Odes, MD

Role: backup

+97252700752

Haggai Bar-Yoseph, MD

Role: primary

+972-4-7772850

Henat Yanai, MD

Role: primary

+972-3-9377040

Adi Lahat -Zok, Prof.

Role: primary

+972-3-302197

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SCRC22051

Identifier Type: OTHER

Identifier Source: secondary_id

MOH_2023-04-30_012589

Identifier Type: REGISTRY

Identifier Source: secondary_id

2203-05901

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

SOR-0351-22-CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.